Drug intelligence / Profile preview

anti-SLAMF6 antibody h20F3ec

Development stage: Preclinical
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Anti-SLAMF6 Antibody h20F3ec (also known as SGN-CD352A) is a recombinant human antibody expressed in Chinese Hamster Ovary (CHO) cells that specifically targets human SLAMF6 (also known as CD352). It is being developed as a targeted immunotherapy, likely as a monoclonal antibody or antibody-drug conjugate, for the treatment of cancer by binding to the SLAMF6 antigen expressed on relevant malignant cells[4][6][8].

Other names: anti-SLAMF6 antibody h20F3ecanti-SLAMF-6 antibody h20F3ecanti-SLAMF 6 antibody h20F3ecSGN-CD352A antibodySGN-CD-352A antibodySGN-CD 352A antibody

Targets

SLAMF6 (Signaling lymphocytic activation molecule family member 6)

Beyond the preview

Go deeper on anti-SLAMF6 antibody h20F3ec.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-SLAMF6 antibody h20F3ec.

Explore the full profile